Published in J Exp Med on December 01, 1984
Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50. Proc Natl Acad Sci U S A (1986) 3.68
Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med (1986) 2.17
Purification to homogeneity of a high molecular weight human B cell growth factor; demonstration of specific binding to activated B cells; and development of a monoclonal antibody to the factor. J Exp Med (1985) 1.47
Defective expression of T cell-associated glycoprotein in severe combined immunodeficiency. J Clin Invest (1986) 1.02
Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells. Immunology (1994) 0.95
Surface proteins and glycoproteins of human leucocytes. Biochem J (1988) 0.83
An activation antigen on a subpopulation of B lymphocytes identified by the monoclonal antibody CMRF-17. Immunology (1989) 0.77
Functional B-lymphocyte surface antigens. Immunology (1986) 0.75
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
Regulation of B-cell growth and differentiation by soluble factors. Annu Rev Immunol (1983) 5.09
B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol (1982) 2.93
Expression of Tac antigen on activated normal human B cells. J Exp Med (1984) 2.76
Stimulation of human B lymphocytes by antibodies to IgM and IgG: functional evidence for the expression of IgG on B-lymphocyte surface membranes. Clin Immunol Immunopathol (1980) 2.00
Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts. Cell (1982) 1.95
Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class. Am J Pathol (1983) 1.93
Polyclonal activation of human lymphocytes in vitro. I. Characterization of the lymphocyte response to a T cell-independent B cell mitogen. J Immunol (1980) 1.92
Detection and functional studies of p60-65 (Tac antigen) on activated human B cells. J Exp Med (1984) 1.84
Biochemical separation of a human B cell mitogenic factor. Proc Natl Acad Sci U S A (1982) 1.68
The role of interleukin 1 in human B cell activation: inhibition of B cell proliferation and the generation of immunoglobulin-secreting cells by an antibody against human leukocytic pyrogen. J Immunol (1983) 1.49
Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody. Proc Natl Acad Sci U S A (1982) 1.13
Nomenclature for lymphokines regulating B lymphocytes. J Immunol (1984) 0.93
An antigen characteristic of hairy cell leukemia cells is expressed on certain activated B cells. J Immunol (1984) 0.89
Recognition by pregnancy serums of non-HL-A alloantigens selectively expressed on B lymphocytes. J Exp Med (1975) 4.96
IgG on lymphocyte surfaces; technical problems and the significance of a third cell population. J Immunol (1975) 4.92
Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J Exp Med (1979) 3.76
CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J Exp Med (1990) 3.67
Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med (1985) 3.48
Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement. J Exp Med (1974) 3.38
Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activity. J Exp Med (1978) 3.18
Occurrence of surface IgM, IgD, and free light chains of human lymphocytes. J Exp Med (1974) 2.93
Peripheral blood Ia-positive T cells. Increases in certain diseases and after immunization. J Exp Med (1980) 2.76
Nature of cold-reactive antibodies to lymphocyte surface determinants in systemic lupus erythematosus. Arthritis Rheum (1975) 2.65
Human T cell activation. I. Monocyte-independent activation and proliferation induced by anti-T3 monoclonal antibodies in the presence of tumor promoter 12-o-tetradecanoyl phorbol-13 acetate. J Exp Med (1985) 2.41
Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. J Exp Med (1978) 2.39
Similar idiotypic specificity for the membrane IgD and IgM of human B lymphocytes. J Immunol (1975) 2.28
Human T cell hybridomas secreting factors for IgA-specific help, polyclonal B cell activation, and B cell proliferation. J Exp Med (1982) 2.27
Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-o-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med (1986) 2.17
Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM. Proc Natl Acad Sci U S A (1993) 2.17
The occurrence of the HL-B alloantigens on the cells of unclassified acute lymphoblastic leukemias. J Exp Med (1975) 2.13
Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. Proc Natl Acad Sci U S A (1974) 2.13
Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med (1988) 2.07
Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. J Exp Med (1988) 2.05
Stimulation of human B lymphocytes by antibodies to IgM and IgG: functional evidence for the expression of IgG on B-lymphocyte surface membranes. Clin Immunol Immunopathol (1980) 2.00
Induction of polyclonal antibody synthesis by human allogeneic and autologous helper factors. J Exp Med (1979) 1.98
The nature of the stimulatory cell in human allogeneic and autologous MLC reactions; role of isolated IgM-bearing B cells. J Immunol (1979) 1.96
Neurofibrillary tangles in senile dementia of the Alzheimer type share an antigenic determinant with intermediate filaments of the vimentin class. Am J Pathol (1983) 1.93
Detection and functional studies of p60-65 (Tac antigen) on activated human B cells. J Exp Med (1984) 1.84
Lymphoblastoid cell lines from patients with chronic lymphocytic leukemia: identification of tumor origin by idiotypic analysis. Proc Natl Acad Sci U S A (1978) 1.78
Patterns of expression of human "Ia-like" antigens during the terminal stages of B cell development. J Immunol (1978) 1.76
T cell helper defect in patients with chronic lymphocytic leukemia. J Immunol (1979) 1.74
B-cell alloantigen Ag 7a in multiple sclerosis. Lancet (1975) 1.67
Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia. Immunol Rev (1979) 1.53
Two types of Ia-positive T cells. Synthesis and exchange of Ia antigens. J Exp Med (1980) 1.47
Anti-CD45 inhibition of human B cell proliferation depends on the nature of activation signals and the state of B cell activation. A study with anti-IgM and anti-CDw40 antibodies. J Immunol (1989) 1.45
Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2. J Exp Med (1994) 1.45
NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin Immunol (2001) 1.42
Mixed lymphocyte culture determinants and C2 deficiency: LD-7a associated with C2 deficiency in four families. J Exp Med (1975) 1.40
Molecular analysis of the induction of immunoglobulin E synthesis in human B cells by interleukin 4 and engagement of CD40 antigen. J Exp Med (1992) 1.38
A model for disease heterogeneity in systemic lupus erythematosus. Relationships between histocompatibility antigens, autoantibodies, and lymphopenia or renal disease. Arthritis Rheum (1989) 1.37
Receptors for IgM on certain human B lymphocytes. J Immunol (1977) 1.37
Immunofluorescent studies on antibodies directed to a buried membrane structure present in lymphocytes and erythrocytes. J Immunol (1975) 1.36
Isolation and immunological characterization of a major surface glycoprotein (gp54) preferentially expressed on certain human B cells. J Exp Med (1979) 1.35
Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. J Exp Med (1986) 1.32
Pre-B cells and other possible precursor lymphoid cell lines derived from patients with X-linked agammaglobulinemia. J Exp Med (1980) 1.28
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia. Proc Natl Acad Sci U S A (1994) 1.26
Intra-alveolar macrophage-inflammatory peptide 2 induces rapid neutrophil localization in the lung. Am J Respir Cell Mol Biol (1996) 1.25
Poor mixed lymphocyte reaction stimulatory capacity of leukemic B cells of chronic lymphocytic leukemia patients despite the presence of Ia antigens. J Clin Invest (1979) 1.24
Human cell lines containing Epstein-Barr virus but distinct from the common B cell lymphoblastoid lines. Proc Natl Acad Sci U S A (1979) 1.24
Polyclonal immunoglobulin secretion in patients with common variable immunodeficiency using monoclonal B cell differentiation factors. J Clin Invest (1984) 1.23
Induction of HLA-DC/DS (LEU 10) antigen expression by human precursor B cell lines. J Exp Med (1983) 1.23
Biogenesis of membrane-bound and secreted immunoglobulins. I. Two distinct translation products of human mu-chain, with identical N-termini and different C-termini. J Exp Med (1980) 1.21
Immunoregulatory role of CD40 in human B cell differentiation. J Immunol (1993) 1.20
Membrane immunoglobulins of B lymphocytes: inability to detect certain characteristic IgM and IgD antigens. J Exp Med (1974) 1.19
Productive infection of cultured human lymphoid cells by adenovirus. J Virol (1987) 1.17
Lymphocyte surface membrane immunoglobulin. Scand J Immunol (1976) 1.17
Hairy cell leukemia: proliferation of a cell with phagocytic and B-lymphocyte properties. Scand J Immunol (1974) 1.13
Rheumatic fever-associated B cell alloantigens as identified by monoclonal antibodies. Arthritis Rheum (1985) 1.13
Discordant phenotype in siblings with X-linked agammaglobulinemia. Am J Hum Genet (1996) 1.12
Rheumatoid factors isolated from patients with autoimmune disorders are derived from germline genes distinct from those encoding the Wa, Po, and Bla cross-reactive idiotypes. J Clin Invest (1991) 1.12
P-selectin and ICAM-1 mediate endotoxin-induced neutrophil recruitment and injury to the lung and liver. Am J Physiol (1999) 1.12
J chain biosynthesis in pre-B cells and other possible precursor B cells. J Exp Med (1981) 1.10
Induction of human antibody responses in vitro with emphasis on allogeneic helper factors. Immunol Rev (1979) 1.09
Intratracheal priming with ovalbumin- and ovalbumin 323-339 peptide-pulsed dendritic cells induces airway hyperresponsiveness, lung eosinophilia, goblet cell hyperplasia, and inflammation. J Immunol (2001) 1.08
TXK, a novel human tyrosine kinase expressed in T cells shares sequence identity with Tec family kinases and maps to 4p12. Hum Mol Genet (1994) 1.07
Hyper IgM syndrome associated with defective CD40-mediated B cell activation. J Clin Invest (1994) 1.05
A novel mutation (Cys145-->Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Mol Med (1996) 1.05
Lack of age-associated immune dysfunction in mucosal-associated lymph nodes. J Immunol (1981) 1.04
Nucleotide sequence analysis of rheumatoid factors and polyreactive antibodies derived from patients with rheumatoid arthritis reveals diverse use of VH and VL gene segments and extensive variability in CDR-3. Scand J Immunol (1992) 1.04
Defective expression of T cell-associated glycoprotein in severe combined immunodeficiency. J Clin Invest (1986) 1.02
Cell-type-specific synthesis of murine immunoglobulin mu RNA from an adenovirus vector. Mol Cell Biol (1986) 1.02
Immune responses to Ro60 and its peptides in mice. I. The nature of the immunogen and endogenous autoantigen determine the specificities of the induced autoantibodies. J Exp Med (1999) 1.02
The 28-kDa/32-kDa activation antigen EA 1. Further characterization and signal requirements for its expression. J Immunol (1988) 1.00
Scanning electron microscopy of human lymphocyte-sheep erythrocyte rosettes. J Exp Med (1974) 0.98
Functional competency of T cell antigen receptors in human thymus. J Immunol (1987) 0.97
Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). J Immunol (2001) 0.96
Studies of the effect of cyclosporine in psoriasis in vivo: combined effects on activated T lymphocytes and epidermal regenerative maturation. J Invest Dermatol (1992) 0.95
Human T cell activation. IV. T cell activation and proliferation via the early activation antigen EA 1. J Exp Med (1989) 0.95
Regulatory role of circulating monocytes in the differentiative and proliferative responses of human B lymphocytes. Clin Immunol Immunopathol (1980) 0.94
Autoantibodies to neurofibrillary tangles and brain tissue in Alzheimer's disease. Establishment of Epstein-Barr virus-transformed antibody-producing cell lines. J Exp Med (1987) 0.94
Human antibodies reactive with beta-amyloid protein in Alzheimer's disease. J Exp Med (1993) 0.93
Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family. J Allergy Clin Immunol (1997) 0.93
Laboratory markers of cardiovascular risk in pediatric SLE: the APPLE baseline cohort. Lupus (2010) 0.92
A rheumatoid factor from a normal individual encoded by VH2 and V kappa II gene segments. Arthritis Rheum (1992) 0.92
Regulatory effects of prostaglandin E2 on the growth and differentiation of human B lymphocytes activated through their CD40 antigen. J Immunol (1994) 0.92
Stimulation of tumor necrosis factor alpha production in human monocytes by inhibitors of protein phosphatase 1 and 2A. J Exp Med (1992) 0.91
IgA specific T-cell factor produced by a human T-T hybridoma. Ann N Y Acad Sci (1983) 0.90
Human T cell activation: differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies. Eur J Immunol (1989) 0.90
Erythrocytotoxicity induced by cancer chemotherapeutic agents. In vitro studies of osmotic fragility and methaemoglobin generation. Scand J Haematol (1980) 0.90
Effect of calorie restriction on the production and responsiveness to interleukin 2 in (NZB X NZW)F1 mice. Clin Immunol Immunopathol (1982) 0.90
Human rheumatoid factors with restrictive specificity for rabbit immunoglobulin G: auto- and multi-reactivity, diverse VH gene segment usage and preferential usage of V lambda IIIb. J Exp Med (1994) 0.90
B lymphocytes lacking surface IG in patients with immune deficiency: initiation of IG synthesis in culture in cells of a patient with thymoma. Birth Defects Orig Artic Ser (1975) 0.89
Biogenesis of membrane-bound and secreted immunoglobulins: two primary translation products of the human delta chain, differentially N-glycosylated to four discrete forms in vivo and in vitro. Proc Natl Acad Sci U S A (1981) 0.89
Prognostic significance of Raynaud's phenomenon in children. Clin Pediatr (Phila) (1983) 0.88
Ro60 peptides induce antibodies to similar epitopes shared among lupus-related autoantigens. J Immunol (2000) 0.87
Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage. Scand J Immunol (2004) 0.87
Diversification, not use, of the immunoglobulin VH gene repertoire is restricted in DiGeorge syndrome. J Exp Med (1993) 0.86